Fasリガンド
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/07/29 14:58 UTC 版)
Fasリガンド（Fas ligand、略号：FasL、別名：CD95L）は、トポロジーII型の膜貫通型蛋白質であり、腫瘍壊死因子（TNF）ファミリーの一員である。アポトーシスを誘導する受容体に結合する。Fasリガンド・受容体相互作用は、免疫系の制御や悪性腫瘍の進行において重要な役割を果たしている。
- ^ a b c GRCh38: Ensembl release 89: ENSG00000117560 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000000817 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Mouse PubMed Reference:
- ^ Yonehara S, Ishii A, Yonehara M (1989). “A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.”. J Exp Med 169 (5): 1747-56. doi:10.1084/jem.169.5.1747. PMC 2189304. PMID 2469768.
- ^ “Death and decoy receptors and p53-mediated apoptosis”. Leukemia 14 (8): 1509–1513. (2000). doi:10.1038/sj.leu.2401865. PMID 10942251.
- ^ “Cytotoxic T cells”. J. Invest. Dermatol. 126 (1): 32–41. (2006). doi:10.1038/sj.jid.5700001. PMID 16417215.
- ^ “Tumor counterattack: fact or fiction?”. Cancer Immunol. Immunother. 54 (11): 1127–1136. (2005). doi:10.1007/s00262-005-0680-7. PMID 15889255.
- ^ a b c d “Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy”. J. Biol. Chem. 280 (12): 11641–7. (March 2005). doi:10.1074/jbc.M411781200. PMID 15659383.
- ^ a b c “Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes”. Cell 114 (2): 181–90. (July 2003). doi:10.1016/s0092-8674(03)00521-x. PMID 12887920.
- ^ “CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway”. EMBO J. 19 (19): 5123–34. (October 2000). doi:10.1093/emboj/19.19.5123. PMC 302100. PMID 11013215.
- ^ a b c “Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178)”. FEBS Lett. 519 (1-3): 50–8. (May 2002). doi:10.1016/s0014-5793(02)02709-6. PMID 12023017.
- ^ a b “Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor”. FEBS Lett. 509 (2): 255–62. (December 2001). doi:10.1016/s0014-5793(01)03174-x. PMID 11741599.
- ^ “Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain”. FEBS Lett. 373 (3): 265–8. (October 1995). doi:10.1016/0014-5793(95)01051-f. PMID 7589480.
- ^ “Identification of amino acid residues important for ligand binding to Fas”. J. Exp. Med. 185 (8): 1487–92. (April 1997). doi:10.1084/jem.185.8.1487. PMC 2196280. PMID 9126929.
- ^ “Characterization of Fas (Apo-1, CD95)-Fas ligand interaction”. J. Biol. Chem. 272 (30): 18827–33. (July 1997). doi:10.1074/jbc.272.30.18827. PMID 9228058.
- ^ “A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis”. J. Biol. Chem. 274 (20): 13733–6. (May 1999). doi:10.1074/jbc.274.20.13733. PMID 10318773.
- ^ “Modulation of dendritic cell differentiation and maturation by decoy receptor 3”. J. Immunol. 168 (10): 4846–53. (May 2002). doi:10.4049/jimmunol.168.10.4846. PMID 11994433.
- ^ “Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer”. Nature 396 (6712): 699–703. (December 1998). doi:10.1038/25387. PMID 9872321.
[続きの解説]
「Fasリガンド」の続きの解説一覧
- 1 Fasリガンドとは
- 2 Fasリガンドの概要
- 3 構造
- 4 機能
- 5 関連項目
- Ｆａｓリガンドのページへのリンク
